New prospective on adjuvant treatment for gastrointestinal stromal tumors / 中华胃肠外科杂志
Chinese Journal of Gastrointestinal Surgery
; (12): 212-215, 2013.
Article
em Zh
| WPRIM
| ID: wpr-314822
Biblioteca responsável:
WPRO
ABSTRACT
Gastrointestinal stromal tumor (GIST) represents the most common mesenchymal tumor of the gastrointestinal tract. With decades of development, surgical excision combined with molecular targeted agents is becoming the mode for the GIST treatment. Imatinib mesylate (IM) is the first-line therapy medicine for GIST adjuvant treatment, and it significantly reduces recurrence or metastasis and increases survival. According to the recently results of SSGXVIII/AIO study, imatinib adjuvant therapy should be administered for at least 3 years for the GIST patients with a high estimated risk of recurrence and metastasis after surgery. Nevertheless, the optimal duration of the adjuvant therapy or the follow-up policy remains unclear, and we look forward to standard assessment criteria for individualized treatment.
Texto completo:
1
Índice:
WPRIM
Assunto principal:
Piperazinas
/
Pirimidinas
/
Cirurgia Geral
/
Benzamidas
/
Quimioterapia Adjuvante
/
Usos Terapêuticos
/
Tumores do Estroma Gastrointestinal
/
Tratamento Farmacológico
/
Mesilato de Imatinib
/
Neoplasias Gastrointestinais
Limite:
Humans
Idioma:
Zh
Revista:
Chinese Journal of Gastrointestinal Surgery
Ano de publicação:
2013
Tipo de documento:
Article